放射学状态不影响中轴型脊柱关节炎的生物制剂应答:BSRBR-AS登记数据
基于英国风湿病学会生物制剂注册中轴型脊柱关节炎队列(BSRBR-AS)的1145例患者,比较放射学阳性与阴性亚组启动生物制剂后的基线特征、1年ASDAS应答及药物生存。结果显示两组基线特征存在差异,但1年ASDAS低疾病状态、临床重要改善和重大改善比例及药物生存曲线均相似。
要点
- 放射学阳性与阴性axSpA患者启动bDMARD后1年ASDAS低疾病状态比例相近。
- 两组ASDAS临床重要改善和重大改善均无统计学显著差异。
- 校正混杂因素后,nr-axSpA/axSpA的药物生存风险比为0.94(95%CI 0.69,1.28)。
核心结论
- 尽管nr-axSpA与r-axSpA基线特征存在差异,但生物制剂应答水平和药物生存相当。
研究设计与样本
- BSRBR-AS为全国性前瞻性队列,纳入符合ASAS标准的中轴型脊柱关节炎患者。
- 分析比较启动bDMARD患者的基线数据,共纳入1145例axSpA患者。
- 采用ASDAS评估1年低疾病状态、临床重要改善和重大改善,并行Cox比例风险分析校正临床相关混杂因素。
主要发现
- r-axSpA亚组男性比例更高、年龄更大、病程更长。
- 基于完整病例分析(290例),1年时两组约三分之二患者达到ASDAS低疾病状态(nr-axSpA 64.2% vs r-axSpA 66.1%)。
- ASDAS临床重要改善(nr-axSpA 50.7% vs r-axSpA 44.7%)和重大改善(nr-axSpA 20% vs r-axSpA 18.7%)在亚组间无统计学显著差异。
- 两亚组药物生存概率曲线相似,校正性别、年龄、基线ASDAS含CRP、吸烟状态、病程、HLA-B27和处方生物制剂后,nr-axSpA/axSpA的风险比为0.94(95%CI 0.69,1.28)。
关键数值与推荐
- ASDAS低疾病状态:nr-axSpA 64.2% vs r-axSpA 66.1%(1年,完整病例分析290例)。
- ASDAS临床重要改善:nr-axSpA 50.7% vs r-axSpA 44.7%(无统计学显著差异)。
- ASDAS重大改善:nr-axSpA 20% vs r-axSpA 18.7%(无统计学显著差异)。
- 药物生存风险比nr-axSpA/axSpA为0.94(95%CI 0.69,1.28),校正性别、年龄、基线ASDAS含CRP、吸烟状态、病程、HLA-B27和处方生物制剂。
临床怎么用
- 对于符合ASAS标准的中轴型脊柱关节炎患者,无论放射学状态如何,均可考虑使用生物制剂并预期相似的应答和药物生存。
局限性
- 应答分析基于完整病例分析(290例),样本量较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe the baseline characteristics, biologic DMARD (bDMARD) response and drug survival of axial SpA (axSpA) patients in the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis (BSRBR-AS) according to radiographic status. METHODS: The BSRBR-AS is a national prospective cohort including axSpA participants classified according to the Assessment of SpondyloArthritis international Society criteria. In this analysis, baseline data of patients starting bDMARDs were compared. Ankylosing Spondylitis Disease Activity Scores (ASDASs) for low disease status, clinically important improvement (CII) and major improvement (MI) at 1 year were used to assess treatment response. Cox proportional hazards analysis was performed after adjusting for clinically relevant confounders. RESULTS: A total of 1145 axSpA patients were included. Higher male prevalence, older age and longer disease duration were seen in the radiographic axSpA (r-axSpA) subgroup. Based on a complete case analysis (290 patients), two-thirds of patients achieved an ASDAS low disease state at 1 year regardless of radiographic status [non-radiographic axSpA (nr-axSpA) 64.2% vs r-axSpA 66.1]. No statistically significant differences were seen between the subgroups in attaining ASDAS CII (nr-axSpA 50.7% vs r-axSpA 44.7%) or MI (nr-axSpA 20% vs r-axSpA 18.7%). Drug survival probability curves were similar for both subgroups and the hazard ratio for nr-axSpA/axSpA was 0.94 (95% CI 0.69, 1.28) when adjusted for sex, age, baseline ASDAS with CRP, smoking status, disease duration, HLA-B27 and prescribed biologic. CONCLUSIONS: Although there appeared to be some differences in the baseline characteristics when exploring this cohort according to radiographic status, which are likely related to the natural history of the disease, the level of biologic response and drug survival was comparable between nr-axSpA and r-axSpA.
引用
- Michelena X, Zhao SS, Dubash S, et al. Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry. Rheumatology (Oxford). 2021. PMID: 33502476. doi:10.1093/rheumatology/keab070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。